CASE REPORT

Radioiodine therapy under rhTSH for follicular thyroid carcinoma with sellar metastasis and non-rising TSH

1SAMEER KAMALAKAR TAYWADE, DNB, 1NISHIKANT AVINASH DAMLE, MD, DNB, 1KUNAL KUMAR, MBBS, 2PIYUSH RANJAN, MS, 3SHIPRA AGGARWAL, MD, 1CHANDRASEKHAR BAL, MD, 4AMANDEEP KUMAR, MCH and 5DEVASANATHIPTHI KANDASAMY, MD

1Department of Nuclear Medicine, A.I.I.M.S, New Delhi, India
2Department of Surgery, A.I.I.M.S, New Delhi, India
3Department of Pathology, A.I.I.M.S, New Delhi, India
4Department of Neurosurgery, A.I.I.M.S, New Delhi, India
5Department of Radiodiagnosis, A.I.I.M.S, New Delhi, India

Address correspondence to: Dr Nishikant Avinash Damle
E-mail: nikan2016@gmail.com

ABSTRACT

Metastasis to the pituitary gland/sella turcica is an uncommon complication of thyroid cancer. Treating this condition is a challenge in the setting of pituitary insufficiency due to this lesion, and recombinant human thyroid-stimulating hormone (rhTSH) stimulation becomes critically essential. We present a rare case of an 82-year-old female patient with follicular carcinoma of the thyroid with metastasis to the sella turcica in addition to multiple skeletal and lung metastases. MRI of the brain showed a hypointense suprasellar lesion on T1 weighted images. The thyroid-stimulating hormone level remained persistently low even 4 weeks after thyroidectomy. A whole-body pertechnetate scan could not localize any abnormal tracer uptake and radioactive iodine uptake was also persistently low. The patient did not have symptoms related to pituitary involvement but TSH and early morning adrenocorticotrophic hormone levels were low. After thorough discussion with the neurosurgeon and radiotherapist, it was decided to start the patient on high-dose radioiodine treatment. Persistently low TSH level was a concern for starting radioiodine therapy. In view of this clinical context, rhTSH stimulation was used to achieve adequate TSH levels prior to radioiodine therapy. Subsequently, the patient was treated with 3.7 GBq (100 mci) of high-dose radioiodine. A post-therapy scan demonstrated radioiodine concentration in the thyroid bed remnant, multiple skeletal lesions and the sellar region. Thus, the use of rhTSH was critical in the management of this patient. It helped in radioiodine treatment by stimulating radioiodine uptake in the remnant and at the metastatic sites.

CASE REPORT

An 82-year-old female patient presented with a history of goitre for 10 years with recent rapid increase in its size, dysphagia and hoarseness of voice for 1 month. She also had low backache and swelling over the right parietal region for 5 months. She had tenderness over the lower lumbar spine on examination. Palpation revealed a large 10 × 8 cm firm mass in the anterior neck, predominantly on the right side, and an immobile hard swelling over the scalp in the right parietal region. Contrast-enhanced CT imaging (Figure 1) performed previously showed a large enhancing mass involving the right lobe and isthmus of the thyroid gland with multiple subcentimetre nodules in bilateral lungs. Fine needle aspiration cytology of the thyroid mass revealed it to be a follicular neoplasm (Bethesda category IV). Based on this clinical information, a tentative diagnosis of metastatic follicular thyroid carcinoma was made. The patient was planned for thyroidectomy followed by radioactive iodine therapy depending on the histopathology. She underwent right hemithyroidectomy in December 2014 under cervical block. Intraoperatively, the surgeon visualized a very small atrophic left lobe of the thyroid but in view of the patient’s overall condition, complete thyroidectomy was considered a difficult procedure to perform. The final histopathology report revealed follicular carcinoma with capsular and vascular invasion.

The patient was referred to the department of nuclear medicine for further management. As per institutional protocol, after hemithyroidectomy, she underwent radioactive iodine uptake (RAIU) and thyroid scan, which showed 1.4% 24 h RAIU and no pertechnetate uptake in the region of the thyroid gland. A pertechnetate whole-body sweep was performed in the same sitting and revealed no uptake in the already known metastatic site. Thyroid function test showed a low normal thyroid-stimulating hormone (TSH) value...
(0.5 μIU ml⁻¹) with normal T3 and T4 levels. Neck ultrasonography showed residual tissue in the neck, predominantly on the left side. In view of the history of a contrast-enhanced CT scan 4 weeks ago, the possibility of iodide interference was considered. The patient was given tablets of furosemide 40 mg day⁻¹ for 2 weeks and a repeat RAIU and pertechnetate study was planned after 2 weeks. The repeat pertechnetate scan did not show abnormal tracer accumulation anywhere in the body and no uptake in the thyroid bed, and there was persistently low RAIU at both 2 (1.5%) and 24 h (1.4%). Repeat thyroid testing showed that the TSH level was 0.5 μIU ml⁻¹, while T3 and T4 levels were now lower than normal. Thyroglobulin level post hemithyroidectomy was reported as > 300 ng ml⁻¹ (normal range 0–52 ng ml⁻¹) by chemiluminescence. The progressively decreasing total T3 and T4 levels ruled out the possibility of extensive functioning metastasis. The possibility of metastases from a second primary was also considered in view of the absence of iodine uptake in the lung and bone lesions. Whole-body ¹⁸F-fludeoxyglucose positron emission tomography–CT (¹⁸F-FDG PET-CT) scan (Figure 2) demonstrated significant residual thyroid tissue in the thyroid bed, multiple skeletal metastases with mild FDG uptake and bilateral pulmonary nodules. In addition to this, there was a small iso- to hypodense lesion in the sellar region with mildly increased FDG uptake. Furthermore, MRI of the brain (Figure 3) showed a hypointense lesion on T₁ weighted images and isointense lesion on T₂ weighted images based over the sphenoid bone in the suprasellar cistern with no bleeding or necrosis. The pituitary gland was seen separately. The right parietal lesion seen in both ¹⁸F-FDG PET-CT scan and MRI showed only dural involvement with no infiltration of adjacent brain parenchyma. The MRI and ¹⁸F-FDG PET-CT findings pointed toward the possibility of pituitary insufficiency owing to sellar metastasis resulting in low TSH. To evaluate the pituitary insufficiency further, serum cortisol and adrenocorticotrophic hormone (ACTH) assay was performed. Early morning (4 am) ACTH was < 5 pg ml⁻¹ (10–60 pg ml⁻¹) and cortisol was 1.16 μg ml⁻¹ (4.3–22.4 μg ml⁻¹). This reconfirmed the diagnosis of pituitary insufficiency due to low TSH level. The treatment option in this clinical context was discussed thoroughly with a neurosurgeon and the radiotherapist. The patient had neither diabetes insipidus nor symptoms of cranial nerve involvement. In view of the extensive metastases and no significant neurological manifestation, surgery, external beam radiotherapy (EBRT) and stereotactic radiosurgery were not considered feasible. Finally, it was decided to use high-dose empirical radioiodine therapy. The persistently low TSH level was deemed to be the cause of low radioiodine uptake; therefore, recombinant human thyroid-stimulating hormone (rhTSH) stimulation was planned. After two rhTSH injections (0.9 mg on two consecutive days), the patient’s TSH levels went up to 664 μIU ml⁻¹. She was subsequently treated with high-dose radioiodine of 3.7 GBq (100 mci). We used a lower dose keeping in mind the persistently low TSH level being the cause of low radioiodine uptake; therefore, recombinant human thyroid-stimulating hormone (rhTSH) stimulation was planned. After two rhTSH injections (0.9 mg on two consecutive days), the patient’s TSH levels went up to 664 μIU ml⁻¹. She was subsequently treated with high-dose radioiodine of 3.7 GBq (100 mci).
mind the proximity of the sellar lesion to the optic chiasma and the fact that the patient was currently experiencing good vision in both eyes. A tapering dose of corticosteroid was administered to avoid any potential mass effect. A post-therapy scan (Figure 4) revealed an intensely iodine-avid remnant in the thyroid bed, multiple skeletal metastasis and faint uptake in the sellar region. Iodine uptake in the sellar region again confirmed the diagnosis of metastasis. The patient was stable during admission and at the time of discharge. An endocrinologist’s opinion was sought for further management of the hypopituitarism. 6 months post radioiodine treatment, the patient was clinically stable and an early second radioiodine therapy was planned under rhTSH stimulation.

**DISCUSSION**

Most of the time, a sellar lesion represents pituitary adenoma. Other aetiologies include Rathke and arachnoidal cysts, craniopharyngiomas, benign non-pituitary tumours and inflammatory lesions. Metastases account for 0.3% of all sellar masses, but a rise in incidence is being observed as life expectancy in malignant diseases is increasing, along with improvements in imaging precision. The most common site of origin in sellar metastases is the lungs (19% of all metastases) in males and breasts in females (53%). Metastases to the pituitary and sella from thyroid carcinoma are very rare, and often such patients have multiple other metastatic sites. In a post-mortem study, isolated involvement of the posterior pituitary was more commonly (52%) found than involvement of both lobes (27%) or the anterior pituitary alone (21%). Predilection for the posterior pituitary was explained by the direct arterial supply and larger area of contact with adjacent dura. To the best of our knowledge, only 22 cases of thyroid cancer with sella turcica/pituitary metastasis (PM) have been reported until now. Of these, nine were from follicular carcinoma, seven were from papillary carcinoma, five were from medullary carcinoma of the thyroid and one was due to anaplastic carcinoma of the thyroid.

Clinical presentation of PM from thyroid cancer is usually owing to cranial nerve involvement or mass effect on the pituitary. However, patients with PM from other cancers generally present with one or more anterior pituitary hormone deficiency and sometimes have hyperprolactinaemia and diabetes insipidus. Unlike other cases reported in the literature, in the present case, the patient did not have cranial nerve involvement or pituitary insufficiency symptoms. The only clue in this patient was the low serum TSH, ACTH and cortisol levels.

Evaluation of patients with sellar metastasis is challenging, as differentiating sellar metastasis from an adenoma on the basis of radiological investigations is sometimes difficult. Both can have sellar enlargement, deformity and erosions. PM usually shows isointense or hypointense lesions on $T_1$ weighted images,
Moreover, in the setting of publications.org/bjrcr Out of these five cases, four patients had pituitary and radioiodine treatment.ing follicular thyroid carcinoma, especially after TSH stimulation and sellar metastases from various malignancies including ioma, pituitary macroadenoma and lymphocytic hypophysitis, as also with sellar metastases from various malignancies including follicular thyroid carcinoma, especially after TSH stimulation and radioiodine treatment. Moreover, in the setting of distant extensive metastases, EBRT, Gamma Knife and surgical excision are not feasible. However, rhTSH stimulation is thought to produce a less marked increase in tumour volume and appears to be the best choice for radioiodine treatment of these metastases. Filipsson et al in a pilot study demonstrated the useful role of rhTSH in patients with central hypothyroidism due to pituitary insufficiency or pituitary damage owing to other causes. However, no clear guidelines are available for the treatment of pituitary/sellar metastasis in particular. So far, radioiodine treatment with the aid of rhTSH has been reported in five such cases.9–12 Out of these five cases, four patients had pituitary insufficiency and one had visual symptoms along with galactorhoea. In our case, low cortisol and ACTH levels along with non-rising TSH levels were the only manifestation of pituitary insufficiency. Considering the overall clinical context and the complications associated with surgery or Gamma Knife therapy, radioiodine treatment under rhTSH stimulation was considered as the first choice. Post-therapy scan after high-dose radioiodine therapy showed radioiodine concentration in the sellar lesion and other metastatic sites.

CONCLUSION
We report a rare case of sellar metastasis from follicular carcinoma without cranial nerve involvement and with partial pituitary insufficiency. Use of rhTSH with radioiodine therapy helped in the management of this patient without any complications.

LEARNING POINTS
1. Although rare, sellar metastasis can be seen in patients with follicular carcinoma of the thyroid.
2. Metastasis to the sellar region can cause pituitary insufficiency possibly owing to vascular compromise.
3. Use of rhTSH can be critical in this clinical scenario.
4. No definite guidelines for management of patients with sellar metastasis from thyroid carcinoma are available; however, 1-131 radioiodine therapy under corticosteroid cover can be used as the first-line of treatment.

CONSENT
Written informed consent was obtained from the patient for publication of this case report, including accompanying images.

REFERENCES
1. Valassi E, Biller BMK, Klibanski A, Sweering B. Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol (Oxf) 2010; 73: 798–807. doi: http://dx.doi.org/10.1111/j.1365-2265.2010.03881.x
2. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96: 1633–41. doi: http://dx.doi.org/10.1210/jc.2011-0168
3. Branch CL, Laws ER Jr. Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab 1987; 65: 469–74. doi: http://dx.doi.org/10.1210/jcem-65-3-469
4. Komninos J, Vlaasopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, et al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2004; 89: 574–80. doi: http://dx.doi.org/10.1210/jc.2003-030395
5. Max MR, Deck MDF, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology 1981; 31: 998–1002. doi: http://dx.doi.org/10.1212/WNL.31.8.998
6. Lim W, Lim DS, Chng CL, Lim AY. Thyroid carcinoma with pituitary metastases: 2 case reports and literature review. Case Rep Endocrinol 2015; 2015: 1–7. doi: http://dx.doi.org/10.1155/2015/252157
7. Chhiber SS, Bhat AR, Khan SH, Wani MA, Ramzan AU, Kirmani AR, et al. Apoplexy in sellar metastasis: a case report and review of literature. Turk Neurosurg 2011; 21: 230–4. doi: http://dx.doi.org/10.5137/1019-5149.TNS.2176-09.1
8. Filipsson H, Nystrom E, Johannsson G. Exploring the use of recombinant human TSH in the diagnosis of central hypothyroidism. Eur J Endocrinol 2008; 159: 153–60. doi: http://dx.doi.org/10.1530/EJE-08-0151
9. Vianello F, Mazzarotto R, Taccaliti A, Lora O, Basso M, Servodio O, et al. Follicular thyroid carcinoma with metastases to the pituitary causing pituitary insufficiency. Thyroid 2011; 21: 921–5. doi: http://dx.doi.org/10.1089/thy.2010.0335
10. Madronio EB, Lantion-Ang FL. The tale of two tumours: an undiagnosed case of papillary thyroid carcinoma. Periodontal Case Rep 2011; 2011: bcr0820114604. doi: http://dx.doi.org/10.1136/bcr.08.2011.4604
11. Maslakiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999; 9: 1023–7. doi: http://dx.doi.org/10.1089/thy.1999.9.1023
12. Yilmazlar S, Kocaeli H, Cordan T. Sella turcica metastasis from follicular carcinoma of thyroid. Neuror Res 2004; 26: 74–8. doi: http://dx.doi.org/10.1179/01616410477026561